Drugs / ET0111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05522309 | Aug 2022 → Dec 2024 | neoplasm | Etern BioPharma (Shanghai) Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET0111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05522309 ↗ |
| Action | Inhibit | “FGFR Inhibitor ET0111” NCT05522309 ↗ |
| Route | Oral | “ET0111 will be administered orally once daily (QD).” NCT05522309 ↗ |